Harrow Acquires Santen’S Branded Ophthalmic Portfolio
07/18/23, 9:03 PM
Location
nashville
Industry
pharmaceutical
biotechnology
health care
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen:
Company Info
Location
Nashville, Arkansas, United States
Company info
Harrow (NASDAQ: HROW) is a growing leader in the ophthalmic healthcare market.
Our mission as a growing leader in the ophthalmic healthcare market is driven by two core values: (1) unyielding dedication to innovation and (2) a mission of providing affordable and accessible medications. We pride ourselves on closely listening to the needs of providers and their patients, so we can do everything in our power to address them with high-quality products and services.
Our worthwhile mission is producing amazing financial results, and because we’ve produced a 72% compound annual growth rate for our first eight years in business, we are one of the fastest-growing ophthalmic pharmaceutical companies in the United States.